INTRODUCTION
Acute lymphocytic leukemia (ALL) has been studied extensively for more than four decades. As a result, much is known about the cellular origin of this leukemia and the genetic mechanisms that lead to malignant transformation [1] [2] [3] . Based on the expression of lineage-specific antigens and the presence of lineage-specific gene rearrangements, ALL cells are known to be derived from either B-or T-cell precursors 4 . In B-lineage ALL, malignant cells often have additional specific genetic abnormalities, which have a significant impact on the clinical course of the disease. In contrast, few molecular abnormalities have been detected in T-ALL and no cytogenetically defined prognostic subgroups have been identified.
The introduction of microarray technology [5] [6] [7] has made it possible to simultaneously quantify expression of thousands of genes within well-defined cellular populations. This method has been used to examine gene expression profiles of malignant cells and recent studies have identified signatures characteristic of various hematologic and non-hematologic tumors [8] [9] [10] [11] [12] [13] [14] [15] . Gene expression profiles have also identified sets of genes that classify subsets of patients with distinct outcomes 13, [15] [16] [17] . Further applications of this technology will determine whether gene expression profiles can be used to identify distinct genetic pathways of malignant transformation in different cell types and whether new targets for therapy can be identified 18 .
In the current study, we used oligonucleotide microarrays to determine gene expres sion profiles in leukemia cells from 33 adult patients with newly diagnosed T -ALL. Analysis of ALL cells included the uniform characterization of immunologic markers, as well as cytogenetic and molecular abnormalities. These experiments only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 4 identified distinct sets of genes associated with response to therapy and long-term maintenance of disease remission. The prognostic significance of 3 of these genes was confirmed by subsequent analysis of an independent set of 18 adult patients with T-ALL treated on the same clinical protocol.
MATERIALS AND METHODS

Patient characteristics
Patients were enrolled in the Italian GIMEMA multicenter clinical trial 0496 for adult patients with newly diagnosed ALL 19 . Written informed consent was obtained from all patients prior to therapy. Pretreatment leukemia samples from bone marrow and/or peripheral blood were centrally processed at the University "La # dupl(12) (q12;q24); add(19)(p13); del(11q)(q21); del(4)(p14). § del(3), del (17) .
¥ del(2)(p16), add(7)(p22), +22; del(7)(p15), t(9;12)(q12;q32), del(13)(q13;q33); der(1;13)(q10;p12),+1,+4,+18+21,+22.
only.
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RNA extraction and oligonucleotide microarray methods
Cryopreserved leukemia cells were rapidly thawed, total RNA was extracted using TRizol reagent (Gibco BRL, Grand Island, NY) and purified using SV Total RNA Isolation System (Promega, Madison, WI), with minor modifications. HGU95aV2 gene chips (Affymetrix, Santa Clara, CA) were used to determine gene expression profiles.
The detailed protocol for sample preparation and microarray processing is available on the manufacturer's website 
Real-time quantitative PCR analysis
Real-time quantitative RT-PCR analysis was performed using an ABI PRISM 7700 Sequence Detection System and the SYBR green I dye (PE Biosystems, Foster City, CA) method as previously described 22 . Real time PCR conditions were as follows:
1 cycle at 50°C for 2 minutes, 1 cycle at 95°C for 10 minutes, 1 cycle at 95°C for 15 seconds, 1 cycle at 60°C for 1 minute, for a total of 40 cycles. For each sample, (C T ) values for GAPDH and -actin were determined for normalization purposes. 
Statistical methods
Affymetrix gene expression data were processed and analyzed with dChip (www.dchip.org), which uses an invariant set normalization method. Model based expressions were computed for each array and probe set 23 . Experimental data quality assessment is provided by dChip software. Hierarchical clustering was used as described by Eisen et al. 24 All other analyses were carried out using the R language (http://cran.rproject.org/) 25 .
Filtering criteria were defined to select genes for further analysis. Gene selection criteria required the expression level to be higher than 100 in >20% of the samples and the ratio of the standard deviation to the mean expression across samples to be between 0.7 and 10 (dChip default values). To select genes that were differentially expressed in subgroups of interest, different statistical tests (e.g. the t-test) were applied and genes selected based on the nominal p-values attained. Genes associated with response to therapy and outcome, were selected using either a t-test (refractory vs complete remission) or a proportional hazards model (duration of complete remission).
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Several methods of analysis utilized cross-validation (CV), a statistical procedure that can be used for estimating the error rate of a prediction method, model selection or variable selection 26 . The basis of cross-validation is to repeatedly partition the data into two groups. One group (the training set) is used to estimate the parameters of a statistical model and the second group (the test set) is used to assess the predictive capability of the model. One form of CV is leave-one-out CV, that is the size of training set vs the test set are n-1:1. In this method, each observation is used as the test set, in turn, and the remaining n-1 observations are the training set. Leave-one-out CV was used for analysis of all gene expression data.
The CV estimation of prediction error rate is obtained by averaging the observed error rate for each of the test sets. To select a model by CV we first determined the CV error rate for all models of interest and then selected the model with the smallest CV error rate. In order to assess the error rate it is important that variable selection is performed within each CV step. Finally, CV can be used for variable selection by selecting the best performing (according to some criterion) variables for each training set and then selecting those appearing more often. We deemed a gene a reliable predictor if it was selected in more than 75% of the training sets. We found this process a valuable mechanism for excluding genes whose apparent effect was only due to a limited number of samples.
Linear discriminant analysis 26 was used to classify patients into specific groups and classification rates were estimated by cross-validation. Proportional hazard models 26 were used to explore the relationship between the duration of CCR and the genes of interest. Kaplan-Meier and log-rank test were used to estimate the probability of CCR in patients with available follow-up information.
RESULTS
Hierarchical clustering reflects the degree of differentiation of leukemic cells
Gene selection criteria were applied to identify genes that were differentially expressed in T-ALL cells from adult patients. As shown in Figure 1 , 313 genes (Table 1, supplemental data) were selected and hierarchical clustering of the 33 samples identified two major groups. Group A included most of the samples classified as relatively undifferentiated T-ALL (2/2 T1, 8/15 T2, and 2 samples not further sub-classified).
Group B included most of the leukemias with phenotypic evidence of further T-cell differentiation (7/15 T2, 10/10 T3 and 2/2 T4 and 2 samples not further sub-classified).
The samples without further phenotypic sub-classification were excluded. A Fisher exact test for association between clusters (group A and B) and levels of T-cell differentiation was performed and proved highly significant (p<0.01). 
Gene expression profile associated with response to therapy
To identify genes associated with response to treatment, we compared expression profiles of T-ALL samples from 25 patients who achieved CR and 6 patients who were refractory to induction therapy. CV for feature selection (a t-test with p-value cut-off of 0.05 was the criterion used to select a gene as best performing) was used to identify 34 genes deemed reliable predictors of response to therapy (Figure 2) . Prediction of response to treatment was assessed using linear discriminant analysis (LDA).
CV for model selection was used to determine the number of genes to use in the LDA. To do this, we left each observation out, in turn. On the test set (n-1), we ranked the 31 reliable predictors by t-test p-value. We then created models with k predictors (from k=1 to k=28, ordered by p-value; beyond 28 numerical problems were encountered) and for each model predicted the outcome of the held out sample. Then for each k, over all CV samples, the prediction error rate was estimated. The minimum error rate occurred at k=25 genes (identified by * in Figure 2 ), where 19 of the 25 responders and 4 of the 6 refractory patients were correctly predicted.
While the profile of patients who achieved CR was heterogeneous, the refractory group showed a homogeneous pattern, characterized by the high expression of IL-8 and reduced expression of the remaining genes. Genes expressed at lower levels in the refractory group include a set of genes belonging to the histone family (H1F0 and H2AFL), several genes that have a role in cell adhesion (CR2, SELL) and cell cycle progression (GFI1, BCL-6). This pattern suggests impaired cell proliferation in T-ALL cases that did not respond to therapy. Another low expressed gene in this group is Maxinteracting protein 1 (MXI1), a transcriptional repressor of myc, which is thought to be a only.
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Gene expression profile associated with long-term outcome
Our next analysis compared patients who relapsed within a period of 2 years with patients who were in CCR for at least 2 years. Patients in CCR whose follow-up was <2 years and the single patient who underwent stem cell transplantation were excluded from this analysis. Eight patients were in CCR and 16 experienced a relapse, 2 patients relapsed >2 years after achieving CR; these latter samples were included in the CCR group. CV for feature selection, with selection based on a univariate Cox model p-value cut-off of 0.05, identified 19 reliable predictors ( Figure 3 ). BUB1B, TTK and CENPF, which play a role in mitotic assembly and mitotic checkpoint, were selectively expressed in T-ALL cells from patients with a long duration of CCR. CD2 was also more highly expressed in this group. Among the few genes with increased expression in the relapse group, we identified AHNAK, which encodes an unusually large 700kD protein with poorly defined function 30 .
CV for model selection was used to determine the number of genes to use in the multivariate Cox model. To do this, we left out each observation in turn. On the test set (n-1), we used the 19 reliable predictors and a forward selection algorithm to fit models with between 1 and 5 genes. We used each model (k from 1 to 5) to predict the status of the held out sample. Then for each k, overall CV samples, we estimated the prediction error rate. Models with k=1 and k=3 tied for the minimum error rate. In both cases we identified genes that were selected more than 75% of the time: for k=1 this was AHNAK and for k=3 AHNAK, CD2 and TTK satisfied this criterion. The mean expression values determined by microarray for AHNAK, CD2 and TTK in the CCR and relapsed groups are shown in Table 2 .
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The clinical impact of this analysis was examined by categorizing the 24 evaluable patients into good or poor risk cohorts based on expression values for AHNAK, TTK and CD2. For each patient in turn, the remaining 23 patients were used to construct a Cox model based on their outcome and observed values of AHNAK, CD2 and TTK. The probability of being in CCR at 2 years was predicted for the held out patient, based exclusively on the observed values of these 3 genes; if that probability exceeded 0.5 a patient was defined as good risk otherwise the patient was defined as poor risk.
Using the 3-gene model, 11 patients were classified as good risk; 6 remain in CCR and 5 relapsed after 9, 12, 14, 30 and 43 months. Thirteen patients were classified as poor risk;
11 have relapsed and 2 remain in CCR. Kaplan-Meier curves comparing duration of remission for the good and poor risk groups determined by this 3 genes model are shown in Figure 4A (log rank test<0.01).
In contrast to pre-B ALL, in which certain molecular aberrations are associated with different outcome, no such well-defined molecular rearrangements are clearly established for T-ALL. Clinical markers such as high white blood cell count (WBC >100,00/µL) at presentation and the degree of differentiation, determined by flow cytometry, of the leukemic blasts have been reported to be associated with outcome 31 .
We therefore also evaluated these conventional approaches for predicting outcome. As shown in Figure 4B and 4C, both conventional parameters appeared to be less predictive than the 3-gene expression model.
For only.
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Real-time quantitative PCR analysis
To confirm the results of microarray analysis, quantitative RT-PCR was performed on 4 genes, IL-8, AHNAK, TTK and CD2. IL-8, the only gene that was more highly expressed in refractory leukemic cells was quantified in 24 samples (6 refractory and 18 CR); AHNAK, TTK and CD2 were quantified in 21 samples (7 CCR and 14 relapse). As shown in Figure 5 Table 3 show a high degree of correlation between all 3 methods used to assess CD2 expression in these samples. Taken together, these results support the validity of the expression data obtained by oligonucleotide microarrays for this set of 4 genes. Assessment of HOX11 demonstrated that this gene was highly expressed in 6 of 33 adult patients in our test set; 1 died in complete remission, 1 was refractory to only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From induction chemotherapy and 3 relapsed. In contrast to pediatric patients where HOX11 expression was associated with a favorable outcome, only 1 of 6 adult patients with highlevel HOX11 expression remains in CCR.
DISCUSSION
The goal of this study was to identify a gene expression signature in adult T-ALL that would have prognostic value in terms of response to induction therapy and longterm outcome. We took advantage of the ongoing policy of characterizing and storing pre-treatment leukemia cells from all patients enrolled in the Italian adult ALL multicenter GIMEMA protocols. Our first approach was to use non-specific filtering criteria to identify genes that were differentially expressed in adult T-ALL samples: a large set of 313 genes was identified and clustering of the 33 patients using these genes identified 2 groups of patients. Further inspection of these groups showed that this clustering mainly reflected the stage of differentiation of the T-ALL blasts 33 . One group primarily included T-ALL with a more differentiated phenotype, whereas the other group included most of the samples with a more immature T-cell phenotype. Although 2 different groups of patients were identified in this analysis, this classification had no correlation with response to induction chemotherapy or with long-term outcome.
To identify genes associated with response to induction therapy, additional filtering criteria were established and 31 genes were selected. Classification errors were assessed by leave-one-out cross validation (CV) that is, leaving one sample out, selecting the top k genes and using the top k genes to predict the class (CR vs refractory) for the left-out sample. The misclassification rate was estimated to be 26%, or the correct only.
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IL-8 is a chemoattractant cytokine reported to play a role in several hematologic malignancies. In chronic lymphocytic leukemia (CLL), increased IL-8 mRNA expression has been associated with prolonged survival of CLL cells 34, 35 , and increased serum levels Induction of CR was associated with increased expression of a diverse set of genes. Many of these genes play a role in the transition from G1 through the S phase of the cell cycle. Many of the agents used for leukemia induction chemotherapy act in a cellcycle dependent fashion and the increased expression of genes associated with cell-cycle progression in these blasts is therefore consistent with the increased susceptibility of highly proliferating cells to treatment. The expression of these genes in leukemia cells that were sensitive to chemotherapy was very heterogeneous. In contrast, low expression of these genes was uniformly found in T-ALL cells from patients who were refractory to treatment.
Comparison of profiles in leukemia cells from patients who remained in CCR for more than 2 years or relapsed within this period identified 19 genes that were only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 26 differentially expressed in these 2 groups. Three genes had increased expression in leukemia cells from patients who relapsed and 16 genes were more highly expressed in blasts from patients who remained in remission. Leave-one out cross-validation was then used to identify those genes that were most consistently associated with duration of remission. This analysis identified 3 genes, AHNAK, CD2 and TTK, that were highly predictive and together correctly classified 71% of outcomes. Individually, AHNAK expression was a better predictor of long remission duration, whereas CD2 and TTK were better predictors of short remission duration (data not shown). Of these genes, AHNAK had increased expression in blasts from patients that subsequently relapsed, whereas CD2
and TTK had increased expression in cases that remained in remission. Using microarray expression values for these 3 genes in leukemia cells, we categorized patients into either poor or good risk groups and found that maintenance of long-term complete remission was significantly different in the 2 groups. Similar results were obtained using data derived from quantitative RT-PCR. Furthermore, these three genes were also evaluated by quantitative RT-PCR in an additional set of 18 patients. Analysis of this independent test set of patients who were treated on the same protocol confirmed the significant association of the expression of these 3 genes with long-term clinical outcome.
AHNAK is an unusually large 700kD protein encoded by an intronless gene located on chromosome 11q12-13 38 . Although the cellular function of AHNAK is unknown, it can become highly phosphorylated and appears to be involved in several signal transduction pathways 30 . The expression of AHNAK is regulated in a cell-cycle dependent manner, with highest levels of RNA and protein occurring during the G1 or G0 phase, and subsequent decrease in proliferating cells. AHNAK phosphorylation also only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 27 appears to be cell cycle dependent with highest levels of unphosphorylated protein occurring in the G1 phase. AHNAK is localized in the cytoplasm at low Ca 52 , reporting that high levels of CD2 antigen determined by flow cytometry were associated with a better outcome. Our analysis of CD2 also found that high-level gene expression was associated with improved outcome in adult patients, confirming these earlier observations, and extending them to adult patients with T-ALL.
Since the number of samples analyzed is relatively small, we have been cautious in our statistical approach and have relied on cross-validation as a basis for determining many of the components of our final model and conclusions. In all cases of model selection, the process of feature selection was carried out separately for each CV iteration. When using CV for gene selection we used a pre-selected value for calling a feature a reliable predictor. The strong concordance between estimates of mRNA abundance between the RT-PCR data and the microarray data was reassuring. Moreover, the strong relationship between duration of remission and the mRNA levels of AHNAK, only.
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TTK and CD2 held regardless of the method used to assay mRNA abundance. Finally, the association of expression of these 3 genes with long-term clinical outcome was confirmed by analysis of an independent set of 18 adult patients with T-ALL who were treated on the same clinical protocol.
The present study investigates, for the first time, the identification of gene expression profiles associated with both short-term and long-term outcome in adult patients with T-ALL. While approximately 70% of pediatric patients with both B-and Tlineage ALL have excellent long-term response to intensive combination chemotherapy, adult patients have a much less favorable outcome. In B-lineage ALL, the poor prognosis of adult patients is partly due to the presence of specific genetic translocations, such as the BCR/ABL or ALL1/AF4 gene rearrangements 1 . In contrast, the poor prognosis of patients with T-ALL has thus far not been attributed to specific molecular rearrangements. Recently, expression of HOX11 32 has been associated with good prognosis in pediatric patients with T-ALL. A related gene, HOX11L2 53 was associated with poor prognosis in these patients. HOX11L2 is not represented in the HGU95aV2 platform, but probes for HOX11 are present and this allowed us to evaluate the association of this gene with outcome in adult patients with T-ALL. In contrast to pediatric patients, expression of HOX11 determined by microarray did not correlate with a more favorable outcome in adult patients.
In an extensive analysis of 360 pediatric patients with ALL, Yeoh et al specifically examined gene expression patterns in 34 patients with T-ALL 15 . HOX11
was not identified as a prognostic marker in these patients but a distinct set of 7 genes was found to be selective expressed in T-ALL cells at high risk for relapse. Thus, we only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From specifically examined the association of these 7 genes with long-term outcome in our cohort of adult patients. Expression of these genes was not significantly associated with remission duration in adult T-ALL. Conversely, of the 3 genes that were most predictive of remission duration in our adult patients, only CD2 was significantly associated with outcome in the pediatric T-ALL patients. As noted previously, this is in agreement with previous studies 52 . Given the marked differences in the biology and response to treatment between pediatric and adult ALL, it is not surprising that different genes are associated with outcome in these patients. Taken together, these observations emphasize the important differences between adult and childhood T-ALL and suggest that the genetic mechanisms of resistance to chemotherapy in these diseases are likely to be very different.
The finding that a single gene was closely associated with resistance to first-line treatment, and that 3 genes were highly predictive of outcome in uniformly treated adults 
